CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 18 enrolled
Drug / intervention
ONO-4538drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02261285
NCT02261285Phase 1Completed
CompareCT.gov

ONO-4538 Multicenter, Open-label, Uncontrolled, Phase I Study in Solid Tumor

Ono Pharmaceutical Co., Ltd.·interventional·Posted Oct 10, 2014·Updated May 6, 2024

In Brief

A Phase 1 clinical trial evaluating ONO-4538 for Advanced Solid Tumors and Recurrent Solid Tumors. Completed, enrolled 18 participants across 5 sites.

Detailed Summary

The objective of the study is to investigate the pharmacokinetics of ONO-4538 administered to Korean patients with advanced or recurrent solid tumors who are refractory or intolerant to standard therapy or for whom no appropriate treatment is available.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors, Recurrent Solid Tumors
CountriesSouth Korea
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 10, 2014
Enrollment StartOct 1, 2014
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 11.7 years ago

Interventions

ONO-4538drug